Clinical orthopaedics and related research
-
Clin. Orthop. Relat. Res. · Mar 2019
Is Obesity Associated With Increased Risk of Deep Vein Thrombosis or Pulmonary Embolism After Hip and Knee Arthroplasty? A Large Database Study.
Deep venous thrombosis (DVT) and pulmonary embolus (PE) remain an important cause of morbidity and mortality after THA and TKA. Prior recommendations have advocated for more aggressive prophylaxis for patients with obesity, whereas the evidence supporting these recommendations is conflicting and often based on underpowered studies. ⋯ Level III, therapeutic study.
-
Clin. Orthop. Relat. Res. · Feb 2019
Comparative StudyRevisions of Modular Metal-on-metal THA Have a High Risk of Early Complications.
The risk of early complications is high after monoblock acetabular metal-on-metal (MoM) THA revisions. However, there is a paucity of evidence regarding clinical complications after isolated head-liner exchange of modular MoM THA. ⋯ Level IV, therapeutic study.
-
Clin. Orthop. Relat. Res. · Feb 2019
Can Machine Learning Methods Produce Accurate and Easy-to-use Prediction Models of 30-day Complications and Mortality After Knee or Hip Arthroplasty?
Existing universal and procedure-specific surgical risk prediction models of death and major complications after elective total joint arthroplasty (TJA) have limitations including poor transparency, poor to modest accuracy, and insufficient validation to establish performance across diverse settings. Thus, the need remains for accurate and validated prediction models for use in preoperative management, informed consent, shared decision-making, and risk adjustment for reimbursement. ⋯ Level III, diagnostic study.
-
Clin. Orthop. Relat. Res. · Feb 2019
Comparative StudyNo Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA.
Aspirin is established as an effective prophylaxis for venous thromboembolism (VTE) after THA; however, there is no consensus as to whether low- or regular-dose aspirin is more effective at preventing VTE. ⋯ Level III, therapeutic study.